Contribution of CYP2D6 to 3,4- methylenedioxymethamphetamine (MDMA) disposition in humans: use of paroxetine as a metabolic inhibitor probe

M Segura, M Farré, S Pichini, AM Peiró, PN Roset, A Ramírez, J Ortuño, R Pacifici, PG Zuccaro, J Segura, la Torre R de

Research output: Contribution to journalArticleResearch

45 Citations (Scopus)
Original languageEnglish
Pages (from-to)649-660
JournalClin Pharmacokinet.
Volume44
Issue number6
Publication statusPublished - 1 Jan 2005

Cite this

Segura, M., Farré, M., Pichini, S., Peiró, AM., Roset, PN., Ramírez, A., Ortuño, J., Pacifici, R., Zuccaro, PG., Segura, J., & de, L. T. R. (2005). Contribution of CYP2D6 to 3,4- methylenedioxymethamphetamine (MDMA) disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet., 44(6), 649-660.